[go: up one dir, main page]

WO2004096235A8 - Analogues de phosphonate anticancereux - Google Patents

Analogues de phosphonate anticancereux

Info

Publication number
WO2004096235A8
WO2004096235A8 PCT/US2004/013121 US2004013121W WO2004096235A8 WO 2004096235 A8 WO2004096235 A8 WO 2004096235A8 US 2004013121 W US2004013121 W US 2004013121W WO 2004096235 A8 WO2004096235 A8 WO 2004096235A8
Authority
WO
WIPO (PCT)
Prior art keywords
phosphonate analogs
cancer
cancer phosphonate
analogs
phosphonate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/013121
Other languages
English (en)
Other versions
WO2004096235A2 (fr
Inventor
Constantine G Boojamara
Carina E Cannizzaro
James M Chen
Xiaowu Chen
Aesop Cho
Lee S Chong
Maria Fardis
Alan X Huang
Choung X Kim
Thorsten A Kirschberg
Steven Krawczyk
Christopher P Lee
Kuei-Ying Lin
Richard L Mackman
David Y Markevitch
Peter H Nelson
David Oare
Vidya K Prasad
Hyung-Jung Pyun
Adrian S Ray
Sundaramoorthi Swaminathan
Will Watkins
Lijun Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Priority to AU2004233989A priority Critical patent/AU2004233989A1/en
Priority to EP04750828A priority patent/EP1617848A2/fr
Priority to BRPI0409680-0A priority patent/BRPI0409680A/pt
Priority to JP2006513405A priority patent/JP2010535701A/ja
Priority to EA200501677A priority patent/EA200501677A2/ru
Priority to MXPA05011287A priority patent/MXPA05011287A/es
Priority to CA002542967A priority patent/CA2542967A1/fr
Priority to PCT/US2004/035136 priority patent/WO2005039552A2/fr
Priority to JP2006536844A priority patent/JP2007520452A/ja
Priority to AU2004283710A priority patent/AU2004283710A1/en
Priority to EP04817344A priority patent/EP1680129A2/fr
Publication of WO2004096235A2 publication Critical patent/WO2004096235A2/fr
Publication of WO2004096235A8 publication Critical patent/WO2004096235A8/fr
Anticipated expiration legal-status Critical
Priority to NO20055592A priority patent/NO20055592L/no
Priority to US11/406,750 priority patent/US20070027116A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4075—Esters with hydroxyalkyl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
    • C07F9/655354—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PCT/US2004/013121 2003-04-25 2004-04-26 Analogues de phosphonate anticancereux Ceased WO2004096235A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
AU2004233989A AU2004233989A1 (en) 2003-04-25 2004-04-26 Anti-cancer phosphonate analogs
EP04750828A EP1617848A2 (fr) 2003-04-25 2004-04-26 Conjugues phosphonate anti-cancereux
BRPI0409680-0A BRPI0409680A (pt) 2003-04-25 2004-04-26 análogos de fosfonato anti-cáncer
JP2006513405A JP2010535701A (ja) 2003-04-25 2004-04-26 抗癌ホスホネートアナログ
EA200501677A EA200501677A2 (ru) 2003-04-25 2004-04-26 Фосфонатсодержащие противораковые соединения (варианты), фармацевтическая композиция (варинты) и лекарственная форма на их основе, способ лечения рака (варианты) и способ подавления неопластических заболеваний (варианты)
MXPA05011287A MXPA05011287A (es) 2003-04-25 2004-04-26 Analogos de fosfonato anti-cancer.
PCT/US2004/035136 WO2005039552A2 (fr) 2003-10-24 2004-10-25 Derives de phosphonate a usage therapeutique
CA002542967A CA2542967A1 (fr) 2003-10-24 2004-10-25 Derives de phosphonate a usage therapeutique
JP2006536844A JP2007520452A (ja) 2003-10-24 2004-10-25 ホスホネート誘導体としてのイノシン一リン酸デヒドロゲナーゼインヒビター
AU2004283710A AU2004283710A1 (en) 2003-10-24 2004-10-25 Inosine monophosphate dehydrogenase inhibitors as phosphonate derivatives
EP04817344A EP1680129A2 (fr) 2003-10-24 2004-10-25 Inhibiteurs de l'inosine monophosphonate deshydrogenase comme derives de phosphonate
NO20055592A NO20055592L (no) 2003-04-25 2005-11-25 Antikreft-fosfonatanaloger
US11/406,750 US20070027116A1 (en) 2003-10-24 2006-04-19 Therapeutic phosphonate derivatives

Applications Claiming Priority (224)

Application Number Priority Date Filing Date Title
US46566803P 2003-04-25 2003-04-25
US46558803P 2003-04-25 2003-04-25
US46533903P 2003-04-25 2003-04-25
US46560703P 2003-04-25 2003-04-25
US46555903P 2003-04-25 2003-04-25
US46546703P 2003-04-25 2003-04-25
US46558903P 2003-04-25 2003-04-25
US46554503P 2003-04-25 2003-04-25
US46558603P 2003-04-25 2003-04-25
US46528703P 2003-04-25 2003-04-25
US46539403P 2003-04-25 2003-04-25
US46584403P 2003-04-25 2003-04-25
US46563103P 2003-04-25 2003-04-25
US46547103P 2003-04-25 2003-04-25
US46556903P 2003-04-25 2003-04-25
US46553103P 2003-04-25 2003-04-25
US46560303P 2003-04-25 2003-04-25
US46556703P 2003-04-25 2003-04-25
US46537703P 2003-04-25 2003-04-25
US46546503P 2003-04-25 2003-04-25
US46561403P 2003-04-25 2003-04-25
US46534303P 2003-04-25 2003-04-25
US46541503P 2003-04-25 2003-04-25
US46557503P 2003-04-25 2003-04-25
US46559403P 2003-04-25 2003-04-25
US46571403P 2003-04-25 2003-04-25
US46532503P 2003-04-25 2003-04-25
US46564103P 2003-04-25 2003-04-25
US60/465,415 2003-04-25
US60/465,575 2003-04-25
US60/465,471 2003-04-25
US60/465,589 2003-04-25
US60/465,465 2003-04-25
US60/465,545 2003-04-25
US60/465,531 2003-04-25
US60/465,377 2003-04-25
US60/465,325 2003-04-25
US60/465,668 2003-04-25
US60/465,339 2003-04-25
US60/465,603 2003-04-25
US60/465,559 2003-04-25
US60/465,641 2003-04-25
US60/465,588 2003-04-25
US60/465,467 2003-04-25
US60/465,586 2003-04-25
US60/465,594 2003-04-25
US60/465,844 2003-04-25
US60/465,614 2003-04-25
US60/465,569 2003-04-25
US60/465,343 2003-04-25
US60/465,394 2003-04-25
US60/465,607 2003-04-25
US60/465,287 2003-04-25
US60/465,567 2003-04-25
US60/465,631 2003-04-25
US60/465,714 2003-04-25
US49331003P 2003-08-07 2003-08-07
US49330303P 2003-08-07 2003-08-07
US60/493,303 2003-08-07
US60/493,310 2003-08-07
US49573603P 2003-08-15 2003-08-15
US49568603P 2003-08-15 2003-08-15
US49575103P 2003-08-15 2003-08-15
US49538703P 2003-08-15 2003-08-15
US49564403P 2003-08-15 2003-08-15
US49564503P 2003-08-15 2003-08-15
US49542603P 2003-08-15 2003-08-15
US49553403P 2003-08-15 2003-08-15
US49541603P 2003-08-15 2003-08-15
US49564703P 2003-08-15 2003-08-15
US49548403P 2003-08-15 2003-08-15
US49576903P 2003-08-15 2003-08-15
US49562903P 2003-08-15 2003-08-15
US49566903P 2003-08-15 2003-08-15
US49539303P 2003-08-15 2003-08-15
US49536203P 2003-08-15 2003-08-15
US49578903P 2003-08-15 2003-08-15
US49552403P 2003-08-15 2003-08-15
US49556503P 2003-08-15 2003-08-15
US49568203P 2003-08-15 2003-08-15
US49552703P 2003-08-15 2003-08-15
US49568503P 2003-08-15 2003-08-15
US49542503P 2003-08-15 2003-08-15
US49552503P 2003-08-15 2003-08-15
US49533903P 2003-08-15 2003-08-15
US49538203P 2003-08-15 2003-08-15
US49529703P 2003-08-15 2003-08-15
US49578403P 2003-08-15 2003-08-15
US60/495,524 2003-08-15
US60/495,425 2003-08-15
US60/495,339 2003-08-15
US60/495,686 2003-08-15
US60/495,565 2003-08-15
US60/495,416 2003-08-15
US60/495,682 2003-08-15
US60/495,669 2003-08-15
US60/495,362 2003-08-15
US60/495,426 2003-08-15
US60/495,629 2003-08-15
US60/495,685 2003-08-15
US60/495,645 2003-08-15
US60/495,297 2003-08-15
US60/495,644 2003-08-15
US60/495,751 2003-08-15
US60/495,393 2003-08-15
US60/495,527 2003-08-15
US60/495,647 2003-08-15
US60/495,769 2003-08-15
US60/495,382 2003-08-15
US60/495,484 2003-08-15
US60/495,789 2003-08-15
US60/495,525 2003-08-15
US60/495,387 2003-08-15
US60/495,534 2003-08-15
US60/495,784 2003-08-15
US60/495,736 2003-08-15
US51396903P 2003-10-24 2003-10-24
US51424703P 2003-10-24 2003-10-24
US51428003P 2003-10-24 2003-10-24
US51414403P 2003-10-24 2003-10-24
US51448103P 2003-10-24 2003-10-24
US51420203P 2003-10-24 2003-10-24
US51436903P 2003-10-24 2003-10-24
US51410803P 2003-10-24 2003-10-24
US51396303P 2003-10-24 2003-10-24
US51395603P 2003-10-24 2003-10-24
US51434603P 2003-10-24 2003-10-24
US51410503P 2003-10-24 2003-10-24
US51415903P 2003-10-24 2003-10-24
US51445203P 2003-10-24 2003-10-24
US51397103P 2003-10-24 2003-10-24
US51392603P 2003-10-24 2003-10-24
US51408403P 2003-10-24 2003-10-24
US51397203P 2003-10-24 2003-10-24
US51411403P 2003-10-24 2003-10-24
US51358803P 2003-10-24 2003-10-24
US51408303P 2003-10-24 2003-10-24
US51411503P 2003-10-24 2003-10-24
US51420703P 2003-10-24 2003-10-24
US51436803P 2003-10-24 2003-10-24
US51413103P 2003-10-24 2003-10-24
US51398003P 2003-10-24 2003-10-24
US51435903P 2003-10-24 2003-10-24
US51394803P 2003-10-24 2003-10-24
US51392303P 2003-10-24 2003-10-24
US51414503P 2003-10-24 2003-10-24
US51430403P 2003-10-24 2003-10-24
US51446203P 2003-10-24 2003-10-24
US51394903P 2003-10-24 2003-10-24
US51392703P 2003-10-24 2003-10-24
US51397903P 2003-10-24 2003-10-24
US51396803P 2003-10-24 2003-10-24
US51411203P 2003-10-24 2003-10-24
US51394403P 2003-10-24 2003-10-24
US51416103P 2003-10-24 2003-10-24
US51442403P 2003-10-24 2003-10-24
US51446103P 2003-10-24 2003-10-24
US60/514,114 2003-10-24
US60/513,969 2003-10-24
US60/513,925 2003-10-24
US60/514,359 2003-10-24
US60/514,113 2003-10-24
US60/514,481 2003-10-24
US60/514,115 2003-10-24
US60/513,956 2003-10-24
US60/513,926 2003-10-24
US60/514,105 2003-10-24
US60/514,461 2003-10-24
US60/514,369 2003-10-24
US60/514,258 2003-10-24
US60/514,083 2003-10-24
US60/514,330 2003-10-24
US60/514,346 2003-10-24
US60/513,963 2003-10-24
US60/513,979 2003-10-24
US60/514,131 2003-10-24
US60/514,235 2003-10-24
US60/513,949 2003-10-24
US60/513,980 2003-10-24
US60/514,393 2003-10-24
US60/514,462 2003-10-24
US60/514,207 2003-10-24
US60/514,298 2003-10-24
US60/514,280 2003-10-24
US60/513,564 2003-10-24
US60/514,159 2003-10-24
US60/514,247 2003-10-24
US60/514,304 2003-10-24
US60/513,974 2003-10-24
US60/514,202 2003-10-24
US60/513,944 2003-10-24
US60/513,588 2003-10-24
US60/513,562 2003-10-24
US60/514,145 2003-10-24
US60/514,325 2003-10-24
US60/514,084 2003-10-24
US60/514,424 2003-10-24
US60/513,971 2003-10-24
US60/514,345 2003-10-24
US60/513,932 2003-10-24
US60/514,394 2003-10-24
US60/514,144 2003-10-24
US60/514,439 2003-10-24
US60/514,368 2003-10-24
US60/513,948 2003-10-24
US60/513,972 2003-10-24
US60/514,112 2003-10-24
US60/514,452 2003-10-24
US60/514,161 2003-10-24
US60/513,923 2003-10-24
US60/513,927 2003-10-24
US60/514,108 2003-10-24
US60/513,968 2003-10-24
US60/519,476 2003-11-12
US60/524,340 2003-11-20
US60/531,960 2003-12-22
US60/531,940 2003-12-22
US60/532,230 2003-12-22
US60/532,160 2003-12-22
US60/532,591 2003-12-23
US60/536,054 2004-01-12
US60/536,007 2004-01-12
US60/536,005 2004-01-12
US60/536,006 2004-01-12

Publications (2)

Publication Number Publication Date
WO2004096235A2 WO2004096235A2 (fr) 2004-11-11
WO2004096235A8 true WO2004096235A8 (fr) 2005-02-24

Family

ID=36146932

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/013121 Ceased WO2004096235A2 (fr) 2003-04-25 2004-04-26 Analogues de phosphonate anticancereux

Country Status (5)

Country Link
EP (1) EP1617848A2 (fr)
KR (1) KR20060061930A (fr)
AU (1) AU2004233989A1 (fr)
BR (1) BRPI0409680A (fr)
WO (1) WO2004096235A2 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429572B2 (en) 2003-05-30 2008-09-30 Pharmasset, Inc. Modified fluorinated nucleoside analogues
US7601820B2 (en) 2004-07-21 2009-10-13 Pharmasset, Inc. Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US8957046B2 (en) 2007-03-30 2015-02-17 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US9045520B2 (en) 2008-12-23 2015-06-02 Gilead Pharmasset Llc Synthesis of purine nucleosides
US9393256B2 (en) 2011-09-16 2016-07-19 Gilead Pharmasset Llc Methods for treating HCV
US9493493B2 (en) 2014-09-15 2016-11-15 The Regents Of The University Of California Nucleotide analogs
US9549941B2 (en) 2011-11-29 2017-01-24 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9579332B2 (en) 2004-07-27 2017-02-28 Gilead Sciences, Inc. Phosphonate analogs of HIV inhibitor compounds

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA014685B1 (ru) * 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
PT3109244T (pt) 2004-09-14 2019-06-04 Gilead Pharmasset Llc ¿preparação de ribofuranosil pirimidinas e purinas 2¿-fluoro-2¿-alquil substituídas ou outras opcionalmente substituídas e os seus derivados
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
WO2008005542A2 (fr) 2006-07-07 2008-01-10 Gilead Sciences, Inc., Composés antiviraux à base de phosphinate
JP5620376B2 (ja) 2008-07-08 2014-11-05 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ阻害剤化合物の塩
EP2370451B1 (fr) 2008-12-02 2016-11-16 Wave Life Sciences Japan, Inc. Procédé pour la synthèse d'acides nucléiques modifiés au niveau de l'atome de phosphore
TW201026715A (en) 2008-12-23 2010-07-16 Pharmasset Inc Nucleoside phosphoramidates
TW201026716A (en) 2008-12-23 2010-07-16 Pharmasset Inc Nucleoside analogs
WO2010120386A1 (fr) * 2009-04-17 2010-10-21 Nektar Therapeutics Conjugués inhibiteur de protéine tyrosine kinase-oligomère
WO2010120388A1 (fr) 2009-04-17 2010-10-21 Nektar Therapeutics Conjugués inhibiteur de protéine tyrosine kinase-oligomère
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
BR112012000828A8 (pt) 2009-07-06 2017-10-10 Ontorii Inc Novas pró-drogas de ácido nucleico e métodos de uso das mesmas
PT3290428T (pt) 2010-03-31 2021-12-27 Gilead Pharmasset Llc Comprimido compreendendo 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2h)-il)¿4¿fluoro¿3¿hidroxi¿4¿metiltetrahidrofuran¿2¿il)metoxi) (fenoxi)fosforil)amino)propanoato de (s)- isopropil cristalino
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
BR112014001244A2 (pt) 2011-07-19 2017-02-21 Wave Life Sciences Pte Ltd métodos para a síntese de ácidos nucléicos funcionalizados
HK1200835A1 (en) 2011-12-20 2015-08-14 Riboscience Llc 4'-azido, 3'-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
WO2013092481A1 (fr) 2011-12-20 2013-06-27 F. Hoffmann-La Roche Ag Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
JP6268157B2 (ja) 2012-07-13 2018-01-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ 不斉補助基
EP2890704B1 (fr) 2012-08-31 2018-02-28 Novartis AG Dérivés de 2'-éthynyle nucléoside de traitement d'infections virales
CN104144682A (zh) 2013-01-31 2014-11-12 吉利德法莫赛特有限责任公司 两个抗病毒化合物的联用制剂
EA201892769A3 (ru) 2013-03-15 2019-08-30 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Сложные диэфиры ациклических нуклеозидфосфонатов
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
UA123533C2 (uk) 2013-05-16 2021-04-21 Рібосаєнс Ллс 4'-фтор-2'-метилзаміщені нуклеозидні похідні
EP2996696A4 (fr) 2013-05-16 2016-12-21 Riboscience Llc Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
KR102239196B1 (ko) 2013-08-27 2021-04-12 길리애드 파마셋 엘엘씨 2종의 항바이러스 화합물의 조합 제제
CN106068325B (zh) 2014-01-16 2021-07-09 波涛生命科学有限公司 手性设计
EP3875462A1 (fr) 2015-09-15 2021-09-08 The Regents of The University of California Analogues nucléotidiques
ES2892402T3 (es) 2017-08-01 2022-02-04 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
AU2018335411B2 (en) 2017-09-21 2024-06-27 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
JP7621974B2 (ja) 2019-05-09 2025-01-27 アリゴス セラピューティクス インコーポレイテッド Ｓｔｉｎｇモジュレータとしての修飾環状ジヌクレオシド化合物
CA3152258A1 (fr) * 2019-09-27 2021-04-01 Sohail F. Tavazoie Compositions et procedes de traitement d'un cancer gastro-intestinal metastasique
WO2024020127A1 (fr) 2022-07-21 2024-01-25 Antiva Biosciences, Inc. Compositions et formes posologiques pour le traitement d'une infection par pvh et d'une néoplasie induite par pvh

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429572B2 (en) 2003-05-30 2008-09-30 Pharmasset, Inc. Modified fluorinated nucleoside analogues
US7601820B2 (en) 2004-07-21 2009-10-13 Pharmasset, Inc. Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives
US9579332B2 (en) 2004-07-27 2017-02-28 Gilead Sciences, Inc. Phosphonate analogs of HIV inhibitor compounds
US9585906B2 (en) 2007-03-30 2017-03-07 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US8957046B2 (en) 2007-03-30 2015-02-17 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US9045520B2 (en) 2008-12-23 2015-06-02 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US9393256B2 (en) 2011-09-16 2016-07-19 Gilead Pharmasset Llc Methods for treating HCV
US9549941B2 (en) 2011-11-29 2017-01-24 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9493493B2 (en) 2014-09-15 2016-11-15 The Regents Of The University Of California Nucleotide analogs
US9801884B2 (en) 2014-09-15 2017-10-31 The Regents Of The University Of California Nucleotide analogs
US10213430B2 (en) 2014-09-15 2019-02-26 The Regents Of The University Of California Nucleotide analogs
US10702532B2 (en) 2014-09-15 2020-07-07 The Regents Of The University Of California Nucleotide analogs
US11344555B2 (en) 2014-09-15 2022-05-31 The Regents Of The University Of California Nucleotide analogs

Also Published As

Publication number Publication date
KR20060061930A (ko) 2006-06-08
BRPI0409680A (pt) 2006-04-18
WO2004096235A2 (fr) 2004-11-11
AU2004233989A1 (en) 2004-11-11
EP1617848A2 (fr) 2006-01-25

Similar Documents

Publication Publication Date Title
WO2004096235A8 (fr) Analogues de phosphonate anticancereux
IL264517A (en) Fatty compounds modified by polyethylene glycol
ZA200700357B (en) Tetrapetide analogs
EP1478648A4 (fr) Composes contenant du phosphore et utilisations associees
AU2002319899A1 (en) Novel resveratrol analogs
EP1610759A4 (fr) Analogues de quinobenzoxazine substitues
AU2003245139A1 (en) Modular mark system
WO2004100960A8 (en) Anti-inflammatory phosphonate compounds
AU2003268787A1 (en) Emulsifier
GB0321999D0 (en) Anti-cancer combinations
SI1628685T1 (sl) Antivirusni fosfonatni analogi
GB0322298D0 (en) Coover
HK1085936A (en) Anti-cancer phosphonate conjugates
HK1080013A (en) Substituted quinobenzoxazine analogs
AU2003245725A1 (en) Phosphine compounds
AU2003221120A1 (en) Remedy for cardiomyopathy
HK1080000A (en) Somatostatin-dopamine chimeric analogs
HK1099773A (en) N-benzenesulfonyl substituted anilino-pyrimidine analogs
AU2003906633A0 (en) Anti-cancer agents
AU2003900207A0 (en) New compounds
HK1085946A (en) Immunomodulator phosphonate conjugates
AU2003903113A0 (en) Phosphonate bearing pro-drugs
HK1086502A (zh) 消炎膦酸化合物
AU2003907158A0 (en) Improvements relating to needles
DE602004030444D1 (en) Antivirale phosphonate analoge

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
D17 Declaration under article 17(2)a
WWE Wipo information: entry into national phase

Ref document number: 1-2005-501635

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 542344

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 170892

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2519840

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004233989

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004233989

Country of ref document: AU

Date of ref document: 20040426

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004233989

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/011287

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2006513405

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004811236X

Country of ref document: CN

Ref document number: 1020057020328

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004750828

Country of ref document: EP

Ref document number: 200501677

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2004750828

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0409680

Country of ref document: BR